Target. Test. Treat: Enabling Smarter Evaluation of ADC Through Patient-Derived Organoids (PDOs)

• Leveraging PDOs as functional ADC patient avatars, preserving tumour heterogeneity and normal tissue biology to reflect clinical efficacy and toxicity
• Capturing ADC responses beyond antigen expression to assess target engagement, internalization, payload sensitivity, and tissue penetration
• Enabling development of next generation PDO therapeutic strategies to allow testing of combination therapies and comparison with SoC data 

Speakers:

Isabella Zampeta

Scientific Business Development Manager

HUB Organoids (A Merck Company)